Frank Asuncion
Amgen (United States)(US)
Publications by Year
Research Areas
Bone Metabolism and Diseases, Bone health and osteoporosis research, Bone health and treatments, Wnt/β-catenin signaling in development and cancer, Connective tissue disorders research
Most-Cited Works
- → Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength(2008)937 cited
- → Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL(2008)432 cited
- → Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia(2006)431 cited
- → Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones(2010)265 cited
- → A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair(2016)251 cited
- → Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats(2010)234 cited
- → Densin-180 forms a ternary complex with the (alpha)-subunit of Ca2+/calmodulin-dependent protein kinase II and (alpha)-actinin.(2001)208 cited
- → Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression(2010)203 cited
- → RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats(2008)129 cited